RecruitingNot Applicable

MicroRNA as Markers in Testicular Cancer

Norway, Sweden350 participantsStarted 2016-12-31

Plain-language summary

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Who can participate

Age range18 Years – 70 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with suspected testicular cancer, referred to orchiectomy. * Patients diagnosed with testicular germ cell cancer. * Age 18-70 years of age. * Must be able receive information and to consent. Exclusion Criteria: * Other prior or concomitant malignancy (other than testicular cancer). * Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.

What they're measuring

miR371 as a biomarker in testicular germ cell cancer at orchiectomy

Timeframe: 5 years

miR371 as a biomarker in testicular germ cell cancer at RPLND

Timeframe: 5 years

miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment

Timeframe: 5 years

miR371 as a biomarker in testicular germ cell cancer and detection of recurrence

Timeframe: 5 years

Trial details

NCT IDNCT04914026

SponsorHaukeland University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Mette Pernille Myklebust, PhD

+47 41684492 mette.pernille.myklebust@helse-bergen.no

View on ClinicalTrials.gov More Testicular Germ Cell Cancer trials